Abstract
We did a systematic review and meta-analysis on the efficacy and safety of the anti-TNF drugs adalimumab, etanercept, golimumab and infliximab used in psoriatic arthritis (PsA) adult treatment. Additionally, we present results of anti-TNF use in real life settings. We searched Embase, Medline, Cochrane Central and LILACS, from inception to 11/08/2013, for studies comparing anti-TNFs with each other or with controls. We included nine randomized controlled trials and six observational studies. ACR20, ACR50, PsARC and PASI75 responses were achieved by more users of anti-TNF than control after up to 24 weeks of treatment. More participants who used etanercept and infliximab achieved ACR70. After all patients originally randomized to anti-TNF or placebo had used anti-TNF for at least 24 weeks, we observed difference only with regard to ACR70 response. Radiographic end points were achieved by more patients in anti-TNF group, and they seem to be time dependent—the longer patients use the drug the better the results. Etanercept and infliximab had worse results on application site reactions, but in general anti-TNF drugs in the regimens studied were as safe as control/placebo. There seems to be no difference in efficacy and effectiveness among anti-TNFs, but superiority head-to-head studies are still needed. Meanwhile, other factors should be taken into account in the choice of medication, such as costs and patient convenience.
Similar content being viewed by others
References
Gottlieb A, Korman NJ, Gordon KB et al (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58(5):851–864
Gladman DD, Antoni C, Mease P et al (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcomes. Ann Rheum Dis 64(suppl 2):ii14–ii17
Husted JA, Gladman DD, Farewell VT, Cook RJ (2001) Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Care Res 45:151–158
Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W (2009) The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 7:25. doi:10.1186/1477-7525-7-25
Lee S, Mendelsohn A, Sarnes E (2010) The burden of psoriatic arthritis: a literature review from a global health systems perspective. J Clin Pharm Ther 35(12):680–689
Rosen C, Mussani F, Chandran V, Eder L, Thavaneswaran A, Gladman D (2012) Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology 51:571–576
Gossec L, Smolen J, Gaujoux-Viala CL et al (2012) European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Arthritis Rheum 71:4–12
Pereda C, Nishishinya M, Martinez Lopez J, Carmona L (2012) Efficacy and safety of DMARDs in psoriatic arthritis: a systematic review. Clin Exp Rheumatol 30(2):282–289
Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane collaboration. www.cochrane-handbook.org
Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Brit Med J 339:b2700
Felson DT, Anderson JJ, Boers M et al (1995) American-College-of-Rheumatology preliminary definition of improvement in rheumatoid-arthritis. Arthritis Rheum 38(6):727–735
Clegg DO, Reda DJ, Mejias E et al (1966) Comparision of sulfassalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 39:2013–2020
Fransen J, van Riel PLCM (2005) The disease activity score and the EULAR response criteria. ClinExpRheumatol 23(Suppl. 39):S93–S99
Fredriksson T, Pettersson U (1978) Severe psoriasis oral therapy with a new retinoid. Dermatologica 157:238–244
Van der Heijde DMFM, van‘t Hof MA, van Riel PLCM et al (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49:916–920
Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 9:789–793
Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey: I. Conceptual framework and item selection. Med Care 30:473–483
McHorney CA, Ware JE Jr, Raczek AE (1993) The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247–263
Cella D, Webster K (1997) Linking outcomes management to quality-of-life measurement. Oncology 11:232–235
Cramer JA, Roy A, Burrell A et al (2008) Medication compliance and persistence:terminology and definitions. Value Health 11(1):44–47
Woodroffe R, Yao GL, Meads C et al (2005) Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Asses 9(21):1–179 (iii–iv)
Higgins JPT, Altman AD, Sterne JAC (2012) Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Altman DG, Sterne JAC (eds) Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. www.cochrane-handbook.org
Hartling L, Hamm M, Milne A et al (2012) Validity and inter-rater reliability testing of quality assessment instruments [internet]. Appendix E, decision rules for application of the Newcastle-Ottawa Scale. Agency for Healthcare Research and Quality (US), Rockville (MD). http://www.ncbi.nlm.nih.gov/books/NBK92291/
Landis JR, Koch GG (1997) The measurement of observer agreement for categorical data. Biometrics 33(1):159–174
Deeks JJ, Higgins J, Altman DG (2012) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. www.cochrane-handbook.org
Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DPM (2009) Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 11:R52. doi:10.1186/ar2670
Saad AA, Ashcroft DM, Watson KD et al (2010) Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology 49:697–705
Saad AA, Ashcroft DM, Watson KD et al (2010) Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthrit Care Res 62(3):345–353
Virkki LM, Sumathikutty BC, Arnio MA et al (2010) Biological therapy for psoriatic arthritis in clinical practice: outcomes up to 2 years. J Rheumatol 37:2362–2368
Saougou I, Markatseli TE, Papagoras C et al (2011) Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study. Semin Arthritis Rheum 40:398–406
Chastek B, Prairie E, Watson C et al (2012) Tumor necrosis factor-blocker therapy persistence, gaps, and switching among patients with psoriatic arthritis. J Am Acad Dermatol 66(4):206 (Suppl 1)
Bonafede M, Johnson BH, Fox KM, Watson C, Gandra SR (2013) Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting. J Dermatolog Treat 24:369–373
Mease P, Gladman D, Ritchlin C et al (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum 52(10):3279–3289
Gladman D, Mease P, Cifaldi M, Perdok R, Sasso E, Medich J (2007) Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 66:163–168
Gladman D, Mease P, Ritchlin C et al (2007) Adalimumab for long-term treatment of psoriatic arthritis. Arthritis Rheum 56(2):476–488
Mease P, Ory P, Sharp J et al (2009) Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 68:702–709
Genovese M, Mease P, Thomason G et al (2007) Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 34:1–5
Mease P, Goffe B, Metz J, Vanderstoep A, Finck B, Burge D (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385–390
Mease P, Kivitz A, Burch F et al (2004) Etanercept treatment of psoriatic arthritis. Arthritis Rheum 50(7):2264–2272
Mease P, Kivitz A, Burch F et al (2006) Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 33(4):712–721
Mease P, Woolley M, Singh A, Tsuji W, Dunn M, Chou C-F (2010) Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. J Rheumatol 37(6):1221–1227
Kavanaugh A, Mcinnes I, Mease P et al (2009) Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis. Arthritis Rheum 60(4):976–986
Kavanaugh A, Van Der Heijde D, Mcinnes I et al (2012) Golimumab in psoriatic arthritis. Arthritis Rheum 64(8):2504–2517
Kavanaugh A, Mcinnes I, Mease P et al (2012) Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomized, placebo-controlled GO-REVEAL study. Ann Rheum Dis 0:1–10
Kavanaugh A, Mease P (2012) Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the longterm extension of a randomized, placebo-controlled study. J Rheumatol 39(suppl. 89):90–93
Kavanaugh A, McInnes IB, Krueger GG et al (2013) Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthrit Care Res 65(10):1666–1673
Antoni C, Kavanaugh A, Kirkham B et al (2005) Sustained benefits of infliximab theray for dermatologic and articular manifestations of psoriatic arthritis. Arthritis Rheum 52(4):1227–1236
Kavanaugh A, Antoni C, Gladman D et al (2006) The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 65:1038–1043
Antoni C, Kavanaugh A, van der Heijde D et al (2008) Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 35(5):869–876
Antoni C, Krueger G, Vlam K et al (2005) Inflixmab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64:1150–1157
Kavanaugh A, Antoni C, Krueger G, Yan S, Bala M, Dooley L, Beautler A, Guzza C, Gladman D (2006) Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 65:471–477
Kavabaungh A, Anatoni C, Mease P, Gladman D, Yan S, Bala M, Dooley L, Beutler A, GuzzoU C, Krueger G (2006) Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol 33(11):2254–2259
van der Heijde D, Kavanaugh A, Gladman D et al (2007) Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment. Arthritis Rheum 56(8):2698–2707
Kavanaugh A, Krueger G, Beutler A et al (2007) Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 66:498–505
Baranauskaite A, Raffayavá H, Kungurov N et al (2012) Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 71:541–548
Atteno M, Peluso R, Costa L, Padula S, Caso F, Iervolino S, Sanduzzi A, Lubrano E, Del Puente A, Scarpa R (2010) Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 29:399–403
Taylor W, Gladman D, Helliwell P et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673
Dougados M, van der Linden S, Juhlin R et al (1991) The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 34:1218–1227
Ravindran V, Scott DL, Choy EH (2008) A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 67:855–859
Saad AA, Symmons DP, Noyce PR et al (2008) Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 35:883–890
Woolacott NF, Khadjesari ZC, Bruce IN et al (2006) Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review. Clin Exp Rheumatol 24:587–593
Ash Z, Gaujoux-Viala C, Gossec L (2012) A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 71:319–326
Finckh A, Liang MH, Mugica C (2006) Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 55(6):864–872
Coates LC, Navarro-Coy N, Brown SR et al (2013) The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord 14:101. doi:10.1186/1471-2474-14-101
Coates LC, Moverley AR, McParland L et al (2013) Results of a randomised controlled trial comparing tight control of early psoriatic arthritis (TICOPA) with standard care: tight control improves outcome. Arthritis Rheum 65(10, supplement):S346
NICE (2011) NICE technology appraisal guidance 220 Golimumab for the treatment of psoriatic arthritis. www.nice.org.uk/guidance/TA220
NICE (2013) NICE technology appraisal guidance 199. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (review of technology appraisal guidance 104 and 125). www.nice.org.uk/guidance/TA199
Bero L, Oostvogel F, Bacchetti P, Lee K (2007) Factors associated with findings of published trials of drug–drug comparisons: why some statins appear more efficacious than others. PLoS Med 4(6):e184. doi:10.1371/journal.pmed.0040184
Lexchin J, Bero LA, Djulbegovic B, Clark O (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326:1167. doi:10.1136/bmj.326.7400.1167
Lubrano E, Marchesoni A, Olivieri I et al (2009) The radiological assessment of axial involvement in psoriatic arthritis: a validation study of the BASRI total and the modified SASSS scoring methods. Clin Exp Rheumatol 27:977–980
Coates L, Tillett W, Chandler D (2012) The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology first published online 25 July 2013. doi:10.1093/rheumatology/ket187
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Lemos, L.L.P., de Oliveira Costa, J., Almeida, A.M. et al. Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatol Int 34, 1345–1360 (2014). https://doi.org/10.1007/s00296-014-3006-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-014-3006-2